Related news from
Fri, 19 Jun 2026 17:10:34 +0000	Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.
Fri, 19 Jun 2026 12:36:00 +0000	CAH Stock Up Nearly 8% YTD: Will the Uptrend Continue in the Rest of 2026? Cardinal Health has gained nearly 8% in 2026 as specialty pharma growth, rising EPS, and expanding healthcare services fuel investor optimism.
Thu, 18 Jun 2026 16:49:00 +0000	COR Stock Down Nearly 18% YTD: Should You Buy, Hold or Sell? COR shares are down 18% YTD, but rising EPS guidance, specialty pharma growth and strategic expansion could make this pullback worth watching.
Thu, 18 Jun 2026 14:33:00 +0000	Cencora Launches Enhanced Nucleus Solution for Specialty Practices COR's enhanced Nucleus platform targets complex specialty medication workflows, with a pilot underway across more than 20 physician practice sites.
Thu, 18 Jun 2026 12:00:00 +0000	Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns Rising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings growth and upside potential.
Wed, 17 Jun 2026 12:55:00 +0000	Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. TPR, VRT, CLS and COR are some such stocks.
Wed, 17 Jun 2026 12:00:00 +0000	Cencora Launches Next-Generation Nucleus® Solution with Multi-Site Pilot Across Specialty Physician Practices CONSHOHOCKEN, Pa., June 17, 2026--Cencora, a global pharmaceutical solutions company, today announced a multi-site pilot of its enhanced Nucleus® inventory management solution, designed to help specialty physician practices manage increasingly complex medication workflows with greater efficiency, visibility and control.
Mon, 15 Jun 2026 20:15:00 +0000	Cencora Announces Samantha Hammock as Chief Human Resources Officer CONSHOHOCKEN, Pa., June 15, 2026--Cencora, Inc. (NYSE: COR) today announced that Silvana Battaglia, Executive Vice President and Chief Human Resources Officer (CHRO), has announced she will retire from the company following a distinguished seven-year tenure. She will be succeeded by Samantha (Sam) Hammock, who will join Cencora as Executive Vice President and CHRO, effective July 13, 2026.
Mon, 15 Jun 2026 15:47:26 +0000	Cardinal Health Stock: Is CAH Outperforming the Healthcare Sector? Cardinal Health has outperformed the healthcare sector over the past year. Moreover, Wall Street analysts are strongly bullish on the stock.
Wed, 10 Jun 2026 16:13:51 +0000	Assessing Cencora (COR) Valuation After Kite CAR T Distribution Deal And Upcoming CFO Transition Cencora (COR) has attracted fresh attention after agreeing to support distribution of Kite’s FDA approved CAR T cell therapies, while also planning a CFO transition to Eva C. Boratto in June 2026. See our latest analysis for Cencora. Recent news around the Kite collaboration and upcoming CFO change comes as the stock price has risen 2.00% over 1 day and 7.08% over 30 days, but is still down 20.19% over 90 days. The 5 year total shareholder return of 147.29% points to a much stronger longer...
Wed, 10 Jun 2026 14:05:45 +0000	Cencora Kite Deal Highlights CAR T Growth And Undervalued Share Price Potential Cencora (NYSE:COR) has entered a major U.S. distribution partnership with Kite Pharma, a Gilead company. The agreement focuses on market access and distribution support for FDA approved CAR T cell therapies across U.S. treatment centers. The collaboration is aimed at easing logistical and administrative hurdles for healthcare providers using these personalized cancer treatments. Cencora comes into this Kite agreement with a mixed share price record. The stock is trading at $279.57, with...
Tue, 09 Jun 2026 15:05:00 +0000	2 Dirt Cheap Healthcare Stocks to Buy With $1,000 Right Now Italian healthcare vials and cartridges maker Stevanato Group and U.S. generic and wholesale pharmaceutical company Cencora are two of the best healthcare buys right now.
Mon, 08 Jun 2026 17:12:00 +0000	Tris Pharma Introduces a New 60 mL Bottle Size for DYANAVEL® XR (amphetamine) Extended-Release Oral Suspension CII A new, smaller 60 mL bottle brings pharmacy-stocking and dosing convenience to a once-daily liquid amphetamine designed for individualized titration in ADHDMONMOUTH JUNCTION, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company advancing transformative targeted CNS therapeutics, today announced the availability of DYANAVEL® XR (amphetamine) extended-release oral suspension, CII (2.5 mg/mL) in a new, smaller 60 mL bottle (NDC 24478-102-02)
Mon, 08 Jun 2026 13:55:23 +0000	Is Cencora Stock Underperforming the Nasdaq? Cencora has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.
Fri, 05 Jun 2026 15:30:12 +0000	Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue? Cencora (COR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Fri, 05 Jun 2026 13:55:02 +0000	Wall Street Analysts Predict a 33.55% Upside in Cencora (COR): Here's What You Should Know The mean of analysts' price targets for Cencora (COR) points to a 33.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wed, 03 Jun 2026 11:05:38 +0000	Is McKesson Stock Underperforming the Dow? McKesson has underperformed the Dow over the past year, but analysts are highly optimistic about the stock’s prospects.
Tue, 02 Jun 2026 12:00:00 +0000	Cencora to Support U.S. Distribution of Kite’s CAR T-Cell Therapies CONSHOHOCKEN, Pa., June 02, 2026--Cencora today announced an agreement with Kite, a Gilead Company, to support the distribution of Kite’s U.S. Food and Drug Administration (FDA)-approved CAR T-cell therapies, Yescarta® (axicabtagene ciloleucel) and Tecartus® (brexucabtagene autoleucel).
Mon, 01 Jun 2026 23:11:42 +0000	Is Cencora’s New CFO, $2 Billion Buyback, and Lawsuit Trio Altering The Investment Case For Cencora (COR)? Cencora has appointed Eva C. Boratto as Executive Vice President and Chief Financial Officer effective June 29, 2026, announced a share repurchase program of up to US$2.00 billion, and is facing a new California labor class action lawsuit. The combination of a seasoned healthcare-focused finance leader joining the company and a very large buyback authorization creates an important moment for reassessing Cencora’s capital allocation and governance profile. We’ll now examine how the...
Mon, 01 Jun 2026 18:39:18 +0000	AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.

If you are already a Value Forum member but are not logged on, click here to log on. If you are a guest, thank you for visiting ValueForum -- click here for information about guest access or click here to join -- a Trial Pass can be purchased for $6.99 to help you decide if you want to commit to longer term membership. Did you know there are customized portals into VF like REITs.ValueForum.com and also My ValueForum which lets you customize your VF experience to the posters and topics that most interest you!